CETUXIMAB IN COMBINATION WITH CISPLATIN PLUS DOCETAXEL TO EVALUATE THE ACTIVITY AND SAFETY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: PHASE II DOCETUX STUDY.

Trial Profile

CETUXIMAB IN COMBINATION WITH CISPLATIN PLUS DOCETAXEL TO EVALUATE THE ACTIVITY AND SAFETY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: PHASE II DOCETUX STUDY.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2011

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms DOCETUX
  • Most Recent Events

    • 09 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top